Verily designed the lab to Freenome’s specifications to foster collaboration after quietly participating in its $65 million financing round in March.

Takeda and BioSurfaces are teaming up to create devices for the treatment of gastrointestinal disease based on the latter's nanofiber technology.

Celgene has announced a new arm of a phase 1b study that will study Novocure’s noninvasive brain cancer therapy alongside a pair of cancer drugs.

IBM and the University of Alberta developed algorithms that predict schizophrenia, which could lead to objective measures to diagnose the disorder.

Mayo Clinic and AliveCor are developing a low-cost, portable screening tool for long QT, which can cause sudden cardiac death.

Simplify Medical raised $21 million in series B funding to support two U.S. pivotal trials of its nonmetal cervical artificial disc.

Quest Diagnostics has completed its acquisition of a pair of laboratory businesses in Texas, establishing a foothold in the southwestern U.S.

The finding suggests doctors could use biomarkers tied to the visual system to spot the disease early and monitor its advance.

A proof-of-concept study suggests that combines AI and the whole-genome sequencing of tumors could scale precision medicine for cancer.

R&D